X4 Pharmaceuticals, Inc. (XFOR:NASDAQ) closed at $3.12 on November 13, 2026, down 1.58% on the day. The stock trades 35.4% below its 52-week high of $4.83 and 28.4% above its 52-week low of $2.43. Over the past year, it lost 14.8%. X4 Pharmaceuticals, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since November 13, 2025, XFOR closed higher on 116 days (46%). Its best day was March 17, 2026 (+18.82%) and its worst was December 1, 2025 (-13.46%). The stock moved 10% or more in a single session 12 times.
Arsanis Inc discovers and develops monoclonal antibodies for the targeted immunotherapy of serious infections. The company's monoclonal antibodies selectively focus on specific pathogens and pathogenic processes which address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. Few of its products candidates are ASN100, for prevention of pneumonia in high risk, mechanically ventilated patients; ASN500, for prevention of respiratory Syncytial virus; ASN300 and ASN200, for prevention and treatment of bacterial infections.
Find more stocks like XFOR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.